NCT00531284View on ClinicalTrials.gov

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

October 31, 2014

Study Completion Date

May 22, 2017

Conditions
Ovarian CancerRenal CancerNon-small Cell Lung CancerSmall Cell Lung CancerSolid TumorsMultiple MyelomaLymphoma
Interventions
DRUG

Carfilzomib

Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion

DRUG

Dexamethasone

Administered orally or by IV infusion prior to carfilzomib

Trial Locations (7)

21201

University of Maryland Greenebaum Cancer Center, Baltimore

60611

Northwestern University, Chicago

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

85258

Pinnacle Oncology, Scottsdale

90210

Tower Cancer Research Foundation, Beverly Hills

07601

Hackensack University Medical Center, Hackensack

37203-1632

The Sarah Cannon Research Institute, Nashville

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00531284 - Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | Biotech Hunter | Biotech Hunter